Healthcare provider profile · identity verified

Fitzgerald Birmingham, MD

Internal Medicine · WASHINGTON, DC · NPI 1609846724

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Amlodipine Besylate	Amlodipine Besylate	590	186
Atorvastatin Calcium	Atorvastatin Calcium	586	175
Rosuvastatin Calcium	Rosuvastatin Calcium	433	137
Hydrochlorothiazide	Hydrochlorothiazide	251	71
Losartan Potassium	Losartan Potassium	228	77
Albuterol Sulfate Hfa	Albuterol Sulfate	203	57
Hydralazine Hcl	Hydralazine Hcl	183	61
Levothyroxine Sodium	Levothyroxine Sodium	183	45
Metoprolol Succinate	Metoprolol Succinate	165	53
Potassium Chloride	Potassium Chloride	148	41
Metformin Hcl	Metformin Hcl	143	39
Ezetimibe	Ezetimibe	138	47
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	117	39
Furosemide	Furosemide	107	33
Lisinopril	Lisinopril	96	29
Carvedilol	Carvedilol	93	31
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	93	30
Nifedipine Er	Nifedipine	91	23
Metoprolol Tartrate	Metoprolol Tartrate	90	25
Famotidine	Famotidine	86	27
Valsartan	Valsartan	86	23
Chlorthalidone	Chlorthalidone	83	18
Simvastatin	Simvastatin	82	29
Eliquis	Apixaban	77	17
Clopidogrel	Clopidogrel Bisulfate	74	25
Fluticasone Propionate	Fluticasone Propionate	74	23
Omeprazole	Omeprazole	74	23
Pantoprazole Sodium	Pantoprazole Sodium	71	33
Pravastatin Sodium	Pravastatin Sodium	67	25
Allopurinol	Allopurinol	64	20
Gabapentin	Gabapentin	62	17
Alendronate Sodium	Alendronate Sodium	61	20
Ozempic	Semaglutide	61	suppressed
Trulicity	Dulaglutide	58	14
Olmesartan Medoxomil	Olmesartan Medoxomil	54	14
Acetaminophen-Codeine	Acetaminophen With Codeine	53	15
Atenolol	Atenolol	53	14
Irbesartan	Irbesartan	47	16
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	47	15
Tradjenta	Linagliptin	47	16
Tamsulosin Hcl	Tamsulosin Hcl	46	15
Tramadol Hcl	Tramadol Hcl	46	12
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	46	12
Colchicine	Colchicine	42	17
Klor-Con M20	Potassium Chloride	42	15
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	42	20
Alprazolam	Alprazolam	37	13
Januvia	Sitagliptin Phosphate	37	suppressed
Metformin Hcl Er	Metformin Hcl	37	suppressed
Olmesartan-Amlodipine-Hctz	Olmesartan/Amlodipin/Hcthiazid	36	12
Doxycycline Monohydrate	Doxycycline Monohydrate	33	27
Nebivolol Hcl	Nebivolol Hcl	33	suppressed
Mometasone Furoate	Mometasone Furoate	31	11
Symbicort	Budesonide/Formoterol Fumarate	31	suppressed
Synthroid	Levothyroxine Sodium	31	suppressed
Irbesartan-Hydrochlorothiazide	Irbesartan/Hydrochlorothiazide	30	suppressed
Azelastine Hcl	Azelastine Hcl	28	suppressed
Janumet	Sitagliptin Phos/Metformin Hcl	28	11
Spironolactone	Spironolactone	28	suppressed
Olmesartan-Hydrochlorothiazide	Olmesartan/Hydrochlorothiazide	27	11
Telmisartan	Telmisartan	27	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	26	suppressed
Mirtazapine	Mirtazapine	25	suppressed
Amlodipine-Olmesartan	Amlodipine Bes/Olmesartan Med	24	suppressed
Felodipine Er	Felodipine	23	suppressed
Sertraline Hcl	Sertraline Hcl	23	suppressed
Budesonide-Formoterol Fumarate	Budesonide/Formoterol Fumarate	22	suppressed
Montelukast Sodium	Montelukast Sodium	22	suppressed
Clonidine Hcl	Clonidine Hcl	20	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	20	suppressed
Glipizide	Glipizide	20	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	20	11
Glipizide Er	Glipizide	19	suppressed
Jardiance	Empagliflozin	19	suppressed
Lovastatin	Lovastatin	19	suppressed
Meclizine Hcl	Meclizine Hcl	19	suppressed
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	18	13
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	18	suppressed
Torsemide	Torsemide	18	suppressed
Acyclovir	Acyclovir	17	suppressed
Bupropion Hcl Sr	Bupropion Hcl	17	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	16	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	16	suppressed
Tizanidine Hcl	Tizanidine Hcl	16	suppressed
Valacyclovir	Valacyclovir Hcl	16	suppressed
Klor-Con M10	Potassium Chloride	15	suppressed
Ultra-Fine Original Pen Needle	Pen Needle, Diabetic	15	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	14	suppressed
Diclofenac Sodium	Diclofenac Sodium	14	suppressed
Febuxostat	Febuxostat	14	suppressed
Mupirocin	Mupirocin	14	suppressed
Ramipril	Ramipril	14	suppressed
Duloxetine Hcl	Duloxetine Hcl	13	suppressed
Farxiga	Dapagliflozin Propanediol	13	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	13	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	12	suppressed
Benazepril Hcl	Benazepril Hcl	12	suppressed
Candesartan Cilexetil	Candesartan Cilexetil	12	suppressed
Enalapril Maleate	Enalapril Maleate	12	suppressed
Lidocaine	Lidocaine	12	suppressed
Tadalafil	Tadalafil	12	suppressed
Tresiba Flextouch U-100	Insulin Degludec	12	suppressed
Donepezil Hcl	Donepezil Hcl	11	suppressed
Glimepiride	Glimepiride	11	suppressed
Ibandronate Sodium	Ibandronate Sodium	11	suppressed
Indapamide	Indapamide	11	suppressed
Novolog Flexpen	Insulin Aspart	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error